Photosoft & Novel Immunotherapy Collab Partnership

Oct 19, 2026 at 5:42 PM EDT · Issued by Percheron Therapeutics Limited via ASX

Filed with ASX · Oct 19, 2026 at 5:42 PM EDT

On 6ix: 6ix.com/news/photosoft-and-novel-immunotherapy-collab-partnership-1

ASX ANNOUNCEMENT INVION AND PERCHERON TO EXPLORE NOVEL COMBINATION OF VISTA IMMUNOTHERAPIES AND PHOTOSOFT™ FOR CANCER • Invion and Percheron Therapeutics to undertake preclinical studies evaluating HMBD- 002, a type of immunotherapy, specifically a VISTA immune checkpoint inhibitor (ICI), in...

View Attachment

6ix hasn’t read this filing yet.

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

PER: Percheron and Invion Explore Cancer Combination TherapyOct 19
Change of Director's Interest NoticeOct 14
Notice under S708AOct 14
Application for quotation of securities - PEROct 13
Notification regarding unquoted securities - PEROct 7

Later from Percheron Therapeutics

Quarterly Activities Report and Appendix 4COct 19
Completion of HMBD-002 Drug Product ManufactureOct 22
Listing Rule waiver to allow quotation of PERAQ optionsOct 29
FDA Clearance for Vanderbilt Health Clinical Trial in AMLNov 1
Prospectus - Placement options and JLM optionsNov 3

All Percheron Therapeutics news releases

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics